Cargando…

Modeling Sarcoglycanopathy in Danio rerio

Sarcoglycanopathies, also known as limb girdle muscular dystrophy 3-6, are rare muscular dystrophies characterized, although heterogeneous, by high disability, with patients often wheelchair-bound by late adolescence and frequently developing respiratory and cardiac problems. These diseases are curr...

Descripción completa

Detalles Bibliográficos
Autores principales: Dalla Barba, Francesco, Soardi, Michela, Mouhib, Leila, Risato, Giovanni, Akyürek, Eylem Emek, Lucon-Xiccato, Tyrone, Scano, Martina, Benetollo, Alberto, Sacchetto, Roberta, Richard, Isabelle, Argenton, Francesco, Bertolucci, Cristiano, Carotti, Marcello, Sandonà, Dorianna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454440/
https://www.ncbi.nlm.nih.gov/pubmed/37628888
http://dx.doi.org/10.3390/ijms241612707
_version_ 1785096194365587456
author Dalla Barba, Francesco
Soardi, Michela
Mouhib, Leila
Risato, Giovanni
Akyürek, Eylem Emek
Lucon-Xiccato, Tyrone
Scano, Martina
Benetollo, Alberto
Sacchetto, Roberta
Richard, Isabelle
Argenton, Francesco
Bertolucci, Cristiano
Carotti, Marcello
Sandonà, Dorianna
author_facet Dalla Barba, Francesco
Soardi, Michela
Mouhib, Leila
Risato, Giovanni
Akyürek, Eylem Emek
Lucon-Xiccato, Tyrone
Scano, Martina
Benetollo, Alberto
Sacchetto, Roberta
Richard, Isabelle
Argenton, Francesco
Bertolucci, Cristiano
Carotti, Marcello
Sandonà, Dorianna
author_sort Dalla Barba, Francesco
collection PubMed
description Sarcoglycanopathies, also known as limb girdle muscular dystrophy 3-6, are rare muscular dystrophies characterized, although heterogeneous, by high disability, with patients often wheelchair-bound by late adolescence and frequently developing respiratory and cardiac problems. These diseases are currently incurable, emphasizing the importance of effective treatment strategies and the necessity of animal models for drug screening and therapeutic verification. Using the CRISPR/Cas9 genome editing technique, we generated and characterized δ-sarcoglycan and β-sarcoglycan knockout zebrafish lines, which presented a progressive disease phenotype that worsened from a mild larval stage to distinct myopathic features in adulthood. By subjecting the knockout larvae to a viscous swimming medium, we were able to anticipate disease onset. The δ-SG knockout line was further exploited to demonstrate that a δ-SG missense mutant is a substrate for endoplasmic reticulum-associated degradation (ERAD), indicating premature degradation due to protein folding defects. In conclusion, our study underscores the utility of zebrafish in modeling sarcoglycanopathies through either gene knockout or future knock-in techniques. These novel zebrafish lines will not only enhance our understanding of the disease’s pathogenic mechanisms, but will also serve as powerful tools for phenotype-based drug screening, ultimately contributing to the development of a cure for sarcoglycanopathies.
format Online
Article
Text
id pubmed-10454440
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104544402023-08-26 Modeling Sarcoglycanopathy in Danio rerio Dalla Barba, Francesco Soardi, Michela Mouhib, Leila Risato, Giovanni Akyürek, Eylem Emek Lucon-Xiccato, Tyrone Scano, Martina Benetollo, Alberto Sacchetto, Roberta Richard, Isabelle Argenton, Francesco Bertolucci, Cristiano Carotti, Marcello Sandonà, Dorianna Int J Mol Sci Article Sarcoglycanopathies, also known as limb girdle muscular dystrophy 3-6, are rare muscular dystrophies characterized, although heterogeneous, by high disability, with patients often wheelchair-bound by late adolescence and frequently developing respiratory and cardiac problems. These diseases are currently incurable, emphasizing the importance of effective treatment strategies and the necessity of animal models for drug screening and therapeutic verification. Using the CRISPR/Cas9 genome editing technique, we generated and characterized δ-sarcoglycan and β-sarcoglycan knockout zebrafish lines, which presented a progressive disease phenotype that worsened from a mild larval stage to distinct myopathic features in adulthood. By subjecting the knockout larvae to a viscous swimming medium, we were able to anticipate disease onset. The δ-SG knockout line was further exploited to demonstrate that a δ-SG missense mutant is a substrate for endoplasmic reticulum-associated degradation (ERAD), indicating premature degradation due to protein folding defects. In conclusion, our study underscores the utility of zebrafish in modeling sarcoglycanopathies through either gene knockout or future knock-in techniques. These novel zebrafish lines will not only enhance our understanding of the disease’s pathogenic mechanisms, but will also serve as powerful tools for phenotype-based drug screening, ultimately contributing to the development of a cure for sarcoglycanopathies. MDPI 2023-08-11 /pmc/articles/PMC10454440/ /pubmed/37628888 http://dx.doi.org/10.3390/ijms241612707 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Dalla Barba, Francesco
Soardi, Michela
Mouhib, Leila
Risato, Giovanni
Akyürek, Eylem Emek
Lucon-Xiccato, Tyrone
Scano, Martina
Benetollo, Alberto
Sacchetto, Roberta
Richard, Isabelle
Argenton, Francesco
Bertolucci, Cristiano
Carotti, Marcello
Sandonà, Dorianna
Modeling Sarcoglycanopathy in Danio rerio
title Modeling Sarcoglycanopathy in Danio rerio
title_full Modeling Sarcoglycanopathy in Danio rerio
title_fullStr Modeling Sarcoglycanopathy in Danio rerio
title_full_unstemmed Modeling Sarcoglycanopathy in Danio rerio
title_short Modeling Sarcoglycanopathy in Danio rerio
title_sort modeling sarcoglycanopathy in danio rerio
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454440/
https://www.ncbi.nlm.nih.gov/pubmed/37628888
http://dx.doi.org/10.3390/ijms241612707
work_keys_str_mv AT dallabarbafrancesco modelingsarcoglycanopathyindaniorerio
AT soardimichela modelingsarcoglycanopathyindaniorerio
AT mouhibleila modelingsarcoglycanopathyindaniorerio
AT risatogiovanni modelingsarcoglycanopathyindaniorerio
AT akyurekeylememek modelingsarcoglycanopathyindaniorerio
AT luconxiccatotyrone modelingsarcoglycanopathyindaniorerio
AT scanomartina modelingsarcoglycanopathyindaniorerio
AT benetolloalberto modelingsarcoglycanopathyindaniorerio
AT sacchettoroberta modelingsarcoglycanopathyindaniorerio
AT richardisabelle modelingsarcoglycanopathyindaniorerio
AT argentonfrancesco modelingsarcoglycanopathyindaniorerio
AT bertoluccicristiano modelingsarcoglycanopathyindaniorerio
AT carottimarcello modelingsarcoglycanopathyindaniorerio
AT sandonadorianna modelingsarcoglycanopathyindaniorerio